Advancing HS Care - An Interactive Learning Experience

Hidradenitis suppurativa (HS) remains a complex, painful chronic inflammatory condition with significant unmet needs in real-world practice. Recent clinical evidence is reshaping how dermatologists think about targeted biologic therapy in this space, and Secukinumab is at the forefront of that evolution. This Innovation Experience brings together two pivotal clinical posters and expert video insights to highlight important Secukinumab data and translate it into practical takeaways you can use in your clinic.

Evolving CSU Management - An Interactive Learning Experience

Chronic Spontaneous Urticaria (CSU) can be unpredictable, persistent, and frustrating for patients and clinicians alike. Emerging data on remibrutinib, a next-generation oral BTK inhibitor, offers promising insights into targeted control of CSU symptoms including improvements in itch and overall disease burden. This Innovation Experience brings together two key clinical posters and expert video insights to help you quickly interpret the evidence and translate it into real-world treatment considerations.

Early Treatment of HS With Secukinumab

Sekukinumab Long-Term Phase 3 Data

Pooled Phase 3 Data From CSU Trials

CSU Disease Activity Data From a Phase 3 Trial

Advancing HS Care - An Interactive Learning Experience

Hidradenitis suppurativa (HS) remains a complex, painful chronic inflammatory condition with significant unmet needs in real-world practice. Recent clinical evidence is reshaping how dermatologists think about targeted biologic therapy in this space, and Secukinumab is at the forefront of that evolution. This Innovation Experience brings together two pivotal clinical posters and expert video insights to highlight important Secukinumab data and translate it into practical takeaways you can use in your clinic.

Evolving CSU Management - An Interactive Learning Experience

Chronic Spontaneous Urticaria (CSU) can be unpredictable, persistent, and frustrating for patients and clinicians alike. Emerging data on remibrutinib, a next-generation oral BTK inhibitor, offers promising insights into targeted control of CSU symptoms including improvements in itch and overall disease burden. This Innovation Experience brings together two key clinical posters and expert video insights to help you quickly interpret the evidence and translate it into real-world treatment considerations.

Early Treatment of HS With Secukinumab

Sekukinumab Long-Term Phase 3 Data

Pooled Phase 3 Data From CSU Trials

CSU Disease Activity Data From a Phase 3 Trial

Advancing HS Care - An Interactive Learning Experience

Hidradenitis suppurativa (HS) remains a complex, painful chronic inflammatory condition with significant unmet needs in real-world practice. Recent clinical evidence is reshaping how dermatologists think about targeted biologic therapy in this space, and Secukinumab is at the forefront of that evolution. This Innovation Experience brings together two pivotal clinical posters and expert video insights to highlight important Secukinumab data and translate it into practical takeaways you can use in your clinic.

Evolving CSU Management - An Interactive Learning Experience

Chronic Spontaneous Urticaria (CSU) can be unpredictable, persistent, and frustrating for patients and clinicians alike. Emerging data on remibrutinib, a next-generation oral BTK inhibitor, offers promising insights into targeted control of CSU symptoms including improvements in itch and overall disease burden. This Innovation Experience brings together two key clinical posters and expert video insights to help you quickly interpret the evidence and translate it into real-world treatment considerations.

Early Treatment of HS With Secukinumab

Sekukinumab Long-Term Phase 3 Data

Pooled Phase 3 Data From CSU Trials

CSU Disease Activity Data From a Phase 3 Trial